These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7577090)

  • 21. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.
    Piccart MJ; Di Leo A; Beauduin M; Vindevoghel A; Michel J; Focan C; Tagnon A; Ries F; Gobert P; Finet C; Closon-Dejardin MT; Dufrane JP; Kerger J; Liebens F; Beauvois S; Bartholomeus S; Dolci S; Lobelle JP; Paesmans M; Nogaret JM
    J Clin Oncol; 2001 Jun; 19(12):3103-10. PubMed ID: 11408507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer.
    Ejlertsen B; Mouridsen HT; Jensen MB; Andersen J; Cold S; Edlund P; Ewertz M; Jensen BB; Kamby C; Nordenskjold B; Bergh J
    Eur J Cancer; 2007 Mar; 43(5):877-84. PubMed ID: 17306974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
    Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D
    J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1).
    Lindman H; Andersson M; Ahlgren J; Balslev E; Sverrisdottir A; Holmberg SB; Bengtsson NO; Jacobsen EH; Jensen AB; Hansen J; Tuxen MK; Malmberg L; Villman K; Anderson H; Ejlertsen B; Bergh J; Blomqvist C;
    Eur J Cancer; 2018 May; 94():79-86. PubMed ID: 29547834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collaborative Cancer Group (ICCG).
    Wils J; Coombes RC; Marty M; Bliss J; Woods E
    Drugs; 1993; 45 Suppl 2():46-50; discussion 49-50. PubMed ID: 7693422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
    Polyzos A; Malamos N; Boukovinas I; Adamou A; Ziras N; Kalbakis K; Kakolyris S; Syrigos K; Papakotoulas P; Kouroussis C; Karvounis N; Vamvakas L; Christophyllakis C; Athanasiadis A; Varthalitis I; Georgoulias V; Mavroudis D
    Breast Cancer Res Treat; 2010 Jan; 119(1):95-104. PubMed ID: 19636702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.
    Bonnefoi H; Biganzoli L; Mauriac L; Cufer T; Schaefer P; Atalay G; Piccart M
    Eur J Cancer; 2003 Jun; 39(9):1277-83. PubMed ID: 12763217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.
    de Azambuja E; Ameye L; Diaz M; Vandenbossche S; Aftimos P; Bejarano Hernández S; Shih-Li C; Delhaye F; Focan C; Cornez N; Vindevoghel A; Beauduin M; Lemort M; Paesmans M; Suter T; Piccart-Gebhart M
    Eur J Cancer; 2015 Nov; 51(17):2517-24. PubMed ID: 26321502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial.
    Focan C; Andrien JM; Closon MT; Dicato M; Driesschaert P; Focan-Henrard D; Lemaire M; Lobelle JP; Longree L; Ries F
    J Clin Oncol; 1993 Jul; 11(7):1253-63. PubMed ID: 8315422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical comparison of safety and efficacy of vinorelbine/epirubicin (NE) with fluorouracil/epirubicin/cyclophosphamide (FEC).
    Yan PW; Huang XE; Jiang Y; Tang JH; Xu HX; Xu X; Jin X
    Asian Pac J Cancer Prev; 2010; 11(4):1115-8. PubMed ID: 21133634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
    Vogt U; Bielawski KP; Bosse U; Schlotter CM
    Oncol Rep; 2004 Nov; 12(5):1109-14. PubMed ID: 15492801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer].
    Feng J; Zheng X; Dai A
    Zhonghua Zhong Liu Za Zhi; 1998 Nov; 20(6):468-70. PubMed ID: 10920949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.
    Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S
    Cancer; 2011 Aug; 117(16):3682-90. PubMed ID: 21305539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group.
    J Clin Oncol; 1991 Feb; 9(2):305-12. PubMed ID: 1988577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Canadian experience with intensive fluorouracil, epirubicin and cyclophosphamide in patients with early stage breast cancer.
    Levine MN; Bramwell V; Pritchard K; Perrault D; Findlay B; Abu-Zahra H; Warr D; Arnold A; Skillings J
    Drugs; 1993; 45 Suppl 2():51-9; discussion 58-9. PubMed ID: 7693423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
    Conti F; Carpano S; Sergi D; Di Lauro L; Amodio A; Vici P; Abbate MI; Ferranti FR; Viola G; Botti C; Foggi P; Sperduti I; Lopez M
    Clin Ter; 2007; 158(4):331-41. PubMed ID: 17953285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
    Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
    Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant chemotherapy for breast cancer--30 years later.
    Levine MN; Whelan T
    N Engl J Med; 2006 Nov; 355(18):1920-2. PubMed ID: 17079767
    [No Abstract]   [Full Text] [Related]  

  • 40. Adjuvant therapy for early breast cancer.
    Costa SD; Bischoff J
    N Engl J Med; 2007 Mar; 356(12):1268-9. PubMed ID: 17377168
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.